P O'Hagan1, S Mercadante2. 1. Healthcare Consultancy, Maidenhead, UK. 2. Pain Relief and Palliative Care Unit, La Maddalena Cancer Centre, Palermo, Italy.
Abstract
BACKGROUND: Confusion remains over the definition of breakthrough cancer pain (BTcP) potentially leading to delayed diagnosis and treatment. METHODS: An on-line survey was conducted in four EU countries among relevant healthcare professionals and cancer patients diagnosed with BTcP. The roles of healthcare professionals (HCPs) were examined and their knowledge and use of available medications recorded. Patients were questioned on how BTcP affected their lives and on the medications they had received/were receiving. RESULTS: There was a 'time lag' of 58 and 13 weeks in Germany and Spain respectively between the initial diagnosis of BTcP and its treatment. Four in ten oncologists across the four countries considered themselves not fully confident in their choice of the appropriate therapy. A quarter of patients in Germany, Italy and Spain and four in ten in France were treated only with increased dosages of the therapy already prescribed for their background pain - often morphine. Almost another quarter received morphine in addition to their treatment for background pain. Oncologists indicated a need for faster-acting treatments revealing a potential lack of awareness of rapid onset oral opioids and patients expressed a desire for more effective pain relief and better psychological support. CONCLUSIONS: There is a need for a universal definition of BTcP to facilitate earlier and more accurate diagnosis. It is essential that BTcP is treated immediately on diagnosis with therapies that more closely mirror its temporal characteristics to ensure that patients' desire for more effective pain relief is fulfilled. SIGNIFICANCE: Many cancer patients suffered episodes of BTcP needlessly over many months due to missed diagnosis. Even after diagnosis, many physicians were not fully confident in their choice of 'rescue' therapy which perhaps is not surprising given the very low level of awareness of treatment guidelines, both national and international.
BACKGROUND: Confusion remains over the definition of breakthrough cancer pain (BTcP) potentially leading to delayed diagnosis and treatment. METHODS: An on-line survey was conducted in four EU countries among relevant healthcare professionals and cancerpatients diagnosed with BTcP. The roles of healthcare professionals (HCPs) were examined and their knowledge and use of available medications recorded. Patients were questioned on how BTcP affected their lives and on the medications they had received/were receiving. RESULTS: There was a 'time lag' of 58 and 13 weeks in Germany and Spain respectively between the initial diagnosis of BTcP and its treatment. Four in ten oncologists across the four countries considered themselves not fully confident in their choice of the appropriate therapy. A quarter of patients in Germany, Italy and Spain and four in ten in France were treated only with increased dosages of the therapy already prescribed for their background pain - often morphine. Almost another quarter received morphine in addition to their treatment for background pain. Oncologists indicated a need for faster-acting treatments revealing a potential lack of awareness of rapid onset oral opioids and patients expressed a desire for more effective pain relief and better psychological support. CONCLUSIONS: There is a need for a universal definition of BTcP to facilitate earlier and more accurate diagnosis. It is essential that BTcP is treated immediately on diagnosis with therapies that more closely mirror its temporal characteristics to ensure that patients' desire for more effective pain relief is fulfilled. SIGNIFICANCE: Many cancerpatients suffered episodes of BTcP needlessly over many months due to missed diagnosis. Even after diagnosis, many physicians were not fully confident in their choice of 'rescue' therapy which perhaps is not surprising given the very low level of awareness of treatment guidelines, both national and international.
Authors: Liz Jamieson; Emily Harrop; Margaret Johnson; Christina Liossi; Christine Mott; Kate Oulton; Simon S Skene; Ian Ck Wong; Richard F Howard Journal: Palliat Med Date: 2021-04-13 Impact factor: 4.762
Authors: Carlos Camps Herrero; Antonio Antón Torres; Juan Jesús Cruz-Hernández; Alfredo Carrato; Manuel Constenla; Eduardo Díaz-Rubio; Margarita Feyjoo Saus; Jesus Garcia-Foncillas; Pere Gascón; Vicente Guillem Journal: J Pain Res Date: 2019-07-29 Impact factor: 3.133
Authors: Katie Greenfield; Simone Holley; Daniel Eric Schoth; Julie Bayliss; Anna-Karenia Anderson; Satbir Jassal; Dilini Rajapakse; Lorna Katharine Fraser; Christine Mott; Margaret Johnson; Ian Wong; Richard Howard; Emily Harrop; Christina Liossi Journal: BMJ Open Date: 2020-03-29 Impact factor: 2.692